StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC – Free Report) in a research report sent to ...

Despite the uptick in shares following the Teoxane proposal, Revance's stock has struggled recently, plunging around 65% last year. Last year, Revance Therapeutics announced the commercial launch ...

Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $6.65. The company has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90.

Crown Labs, which agreed to acquire Revance Therapeutics for $6.66 a share in cash last month, was expected to start a tender offer by a Friday deadline, according to an 8-K filing from Aug. 28.

THE LAWSUIT: A class action securities lawsuit was filed against Revance Therapeutics, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud ...

NEW YORK, March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of RVNC ...

Crinetics Pharmaceuticals said it has hired the chief financial officer of Revance Therapeutics to replace its outgoing finance chief. The clinical-stage pharmaceutical company said Monday that ...

Dermata expects to announce topline results from its XYNGARI™ Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical ...

We are also excited to have recently signed a collaboration agreement with Revance to progress our topical botulinum toxin program forward with an approved toxin product, DAXXIFY®. We believe ...